RxDoctor Payments Data

Carlos Carretero Rodriguez, MD

Internal Medicine · San Antonio, TXNPI 1851434435

Payments from drug & device makers

$491in general payments, 2019–2025

Across 24 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$176
  • Amgen$116
  • Astellas Pharma US Inc$44
  • Pfizer$25
  • Merck$23
  • Si-bone, Inc.$22
  • plus $85 from 6 others

What the payments were for

  • Food & beverage$491100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$491 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$65,006
Medicare patients
184
Services billed
854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$140,091
JanuviaSitagliptin Phosphate50$56,363
MounjaroTirzepatide31$53,309
JardianceEmpagliflozin28$40,972
TrulicityDulaglutide26$35,775
EliquisApixaban38$32,200
RybelsusSemaglutide13$23,632
LinzessLinaclotide17$17,627
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,361
FarxigaDapagliflozin Propanediol11$12,986
Synjardy XrEmpagliflozin/Metformin Hcl11$12,903
Omeprazole190$3,500
LantusInsulin Glargine,hum.Rec.Anlog35$3,400
Atorvastatin Calcium302$3,321
Ibandronate Sodium60$2,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$13$163,723125 claims
Lilly USA, LLCMounjaro, Trulicity$12$89,08457 claims
MerckJanuvia$23$56,36350 claims
PfizerEliquis$25$32,20038 claims
AbbVieLinzess$19$17,62717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →